These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33762203)

  • 1. Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence.
    Laukhtina E; Abufaraj M; Al-Ani A; Ali MR; Mori K; Moschini M; Quhal F; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NC; Fajkovic H; Soria F; Enikeev D; Shariat SF;
    Eur Urol Focus; 2022 Mar; 8(2):447-456. PubMed ID: 33762203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.
    Tabayoyong WB; Kamat AM; O'Donnell MA; McKiernan JM; Ray-Zack MD; Palou J; Brausi M; Black PC; Williams SB
    Eur Urol Focus; 2018 Jul; 4(4):512-521. PubMed ID: 30190111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
    Tan WS; Steinberg G; Witjes JA; Li R; Shariat SF; Roupret M; Babjuk M; Bivalacqua TJ; Psutka SP; Williams SB; Cookson MS; Palou J; Kamat AM
    Eur Urol Oncol; 2022 Oct; 5(5):505-516. PubMed ID: 35718695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Huang Z; Liu H; Wang Y; Zhang C; Xu T
    Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
    Kawada T; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Chlosta M; Pradere B; Teoh JY; Babjuk M; Araki M; Shariat SF
    Urol Oncol; 2023 Jun; 41(6):261-273. PubMed ID: 37137745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
    Chen S; Zhang N; Shao J; Wang X
    Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
    Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials.
    Quan Y; Jeong CW; Kwak C; Kim HH; Kim HS; Ku JH
    Medicine (Baltimore); 2017 Oct; 96(42):e8300. PubMed ID: 29049231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.
    Rahman ZA; Hidayatullah F; Lim J; Hakim L
    Arch Ital Urol Androl; 2024 Feb; 96(1):12154. PubMed ID: 38363237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.